Top

Published in:

01-03-2006

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

Authors: Eric Winquist, Jennifer Knox, Jean-Pierre Ayoub, Lori Wood, Nancy Wainman, Gregory K. Reid, Laura Pearce, Ajit Shah, Elizabeth Eisenhauer

Published in: Investigational New Drugs | Issue 2/2006

Title: Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
Authors: Eric Winquist
Jennifer Knox
Jean-Pierre Ayoub
Lori Wood
Nancy Wainman
Gregory K. Reid
Laura Pearce
Ajit Shah
Elizabeth Eisenhauer
Publication date: 01-03-2006
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-006-5938-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2006

Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer